Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Business Wire•02/11/2026•16:05 ET
0
Key Highlights
- ➤Spruce Biosciences (SPRB) CEO Javier Szwarcberg will join a November 10 healthcare conference fireside chat
- ➤Tralesinidase alfa remains in late-stage development for pediatric MPS IIIB
- ➤TA-ERT has received four FDA designations, including Breakthrough Therapy and Fast Track
- ➤MPS IIIB has no FDA-approved therapies, according to the company
Spruce Biosciences to Participate in the Guggenheim 3(rd) Annual Healthcare Innovation Conference
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 3(rd) Annual Healthcare Innovation Conference on November 10, 2026 at 11:30 a.m. ET in Boston, MA.
Get started
Create a free account to read the full story.